Pilot Pharmaceutical Biotechnology plans to acquire all the shares of Conflux to enter the blockchain field
2025-07-01 06:40:03
Hong Kong-listed Linghang Pharmaceutical Biotechnology Co., Ltd. (00399) announced the signing of a memorandum of understanding to acquire the entire equity of a target company, provided that the target company completes the acquisition of Conflux blockchain-related assets. The acquisition consideration will be paid in cash, company shares or convertible bonds, the specific amount to be determined. The memorandum of understanding is valid for 12 months, during which the seller cannot negotiate with third parties over the equity of the target company. This move is designed to help Linghang Pharmaceutical expand its blockchain technology business, diversify its business and find new profit growth points. The transaction is subject to the signing of a formal agreement before it can be completed.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
